BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 04, 2005
 |  BioCentury  |  Finance

Genentech supersizes

Unlike the first quarter, where the overriding story was the Tysabri disaster, the second quarter had a more positive lead topic - the solid performance of Genentech Inc. DNA enjoyed a spate of positive news flow, including data that could expand the use of cancer drugs Avastin bevacizumab and Herceptin trastuzumab. The company also had positive Phase III data for its Lucentis ranibizumab...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >